13 results
8-K
EX-99.6
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
is liable to provide ‘no fault’ compensation to any study subject injured in the clinical trial.
Prior to commencing a clinical trial, the sponsor
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
product candidates. Such events could subject Kineta to costly litigation, require Kineta to pay substantial amounts of money to injured patients
424B3
KA
Kineta Inc
10 Nov 22
Prospectus supplement
4:21pm
substantial amounts of money to injured patients, delay, negatively impact or end Kineta’s opportunity to receive or maintain regulatory approval
8-K
EX-10.1
mqvaz8tjf gjyj6e88
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
S-4
EX-10.18
swwmdq ytw
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm
- Prev
- 1
- Next